2.Hens, N, et al. Seventy five years of estimating the force of infection from current status data, Epidemiology and Infection 2010; 138: 802–812.
3.Sun, J. The Statistical Analysis of Interval-Censored Failure Time Data. New York: Springer, 2006.
4.Lindsey, JC, Ryan, LM. Tutorial in biostatistics methods for interval-censored data. Statistics in Medicine 1998; 17: 219–238.
5.Dorey, FJ, Little, RJA, Schenker, N. Multiple imputation for threshold-crossing data with interval-censoring. Statistics in Medicine 1993; 12: 1589–1603.
6.Del Fava, , et al. Joint modeling of HCV and HIV infections among injecting drug users in Italy using repeated cross-sectional prevalence data. Statistical communications in infectious diseases. Published online: 24 May 2011. doi:10.2202/1948-4690.1009.
7.Mathei, C, et al. Evidence for a substantial role of sharing of injecting paraphernalia other than syringes/needles to the spread of hepatitis C among injecting drug users. Journal of Viral Hepatitis 2006; 13: 560–570.
8.Namata, H. Flexible statistical models for microbial risk assessment and infectious diseases [dissertation]. Diepenbeek, Belgium: Hasselt University, 2008, pp. 69–92.
9.Platt, L, et al. Measuring risk of HIV and HCV among injecting drug users in the Russian Federation. European Journal of Public Health 2009; 19: 428–433.
10.Sutton, A, et al. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales. BMC Infectious Diseases. Published online: 8 June 2006. doi:10.1186/1471-2334-6-93.
11.Sutton, A, et al. A comparison between the force of infection estimates for blood-borne viruses in injecting drug user populations across the European Union: a modelling study. Journal of Viral Hepatitis 2008; 15: 809–816.
12.Amsterdam Cohort Studies on HIV (ACS). Annual report 2008. Technical report, Amsterdam Cohort Studies on HIV infection.
13.Klein, J, Moeschberger, M. Survival Analysis techniques for Censored and Truncated Data. New York: Springer, 2003, pp. 393–423.
14.Turnbull, BW. The empirical distribution with arbitrarily grouped censored and truncated data, Journal of the Royal Statistical Society, Series B 1976; 38: 290–295.
15.Dempster, AP, Laird, NM, Rubin, DB. Maximum likelihood from incomplete data via the EM algorithm (with discussion). Journal of the Royal Statistical Society, Series B 1977; 39: 1–38.
16.Pencina, MJ, Larson, MG, D'Agostino, RB. Choice of time scale and its effect on significance of predictors in longitudinal studies. Statistics in Medicine 2007; 26: 1343–1359.
17.Van den Berg, CHSB, et al. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users, European Journal of Epidemiology 2007; 22: 183–193.
18.Van den Berg, CHSB, et al. Full participation in harm reduction programmes is associated with risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies, Addiction 2007; 102: 1454–1462.
19.Van de Laar, TJW, et al. Changes in risk behavior and dynamics of hepatitis C virus infections among young drug users in Amsterdam, the Netherlands, Journal of Medical Virology 2005; 77: 509–518.
20.Wiessing, L, et al. Injecting drug use in Europe: stable or declining. Eurosurveillance 2010; 15: 17–18.
21.Welp, EA, et al. HIV prevalence and risk behaviour in young drug users in Amsterdam. AIDS 2002; 16: 1279–1284.
22.Van Ameijden, EJC, Coutinho, RA. Large decline in injecting drug use in Amsterdam, 1986–1998: explanatory mechanisms and determinants of injecting transitions. Journal of Epidemiology & Community Health 2001; 55: 356–363.
23.Hahn, JA, et al. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology 2001; 34: 180–187.
24.Thorpe, LE, et al. Hepatitis C virus infection: prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997–1999. Journal of Infectious Diseases 2000; 182: 1588–1594.
25.Miller, CL, et al. Opportunities for prevention: Hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology 2002; 36: 737–742.
26.Miller, M, et al. HIV and hepatitis C virus risk in new and longer-term injecting drug users in Oslo, Norway. Journal of Acquired Immune Deficiency Syndromes 2003; 33: 373–379.
27.Hens, N, et al. The correlated and shared gamma frailty model for bivariate current status data: an illustration for cross-sectional serological data. Statistics in Medicine 2009; 28: 2785–2800.